Oral Multiple Sclerosis Drug More Effective, According to Trial Results
Thursday January 8, 2009
Fingolimod, an oral drug under development for treating multiple sclerosis, was shown to be more effective than current treatments in a recent trial.
The trial consisted of over 1,200 individuals receiving either fingolimod or Avonex. On average, the people receiving Avonex had 0.33 relapses per year while the people on fingolimod had between 0.16 and 0.20 relapses (depending on dosage tested). ...